文献速递淋巴瘤

组蛋白去乙酰化酶抑制剂莫西司他治疗复发或难治性淋巴瘤的2期研究

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
PubMed 文献 · Br J Haematol · 2017-04-25

这项2期研究评估了同型选择性组蛋白去乙酰化酶(HDAC)抑制剂莫西司他治疗复发或难治性(R/R)弥漫大B细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)的疗效。72例患者接受莫西司他治疗(起始剂量70-110 mg,每周三次,4周为一周期)。DLBCL队列(n=41)最佳总缓解率为18.9%(95%CI 7.2, 32.2),FL队列(n=31)为11.5%(95%CI 1.7, 20.7);单药活性有限,但获得临床获益的患者实现了长期疾病控制,安全性可接受。

要点

  • DLBCL队列最佳总缓解率18.9%(95%CI 7.2, 32.2),FL队列11.5%(95%CI 1.7, 20.7)
  • DLBCL队列54.1%、FL队列73.1%的患者获得临床获益(缓解或疾病稳定)
  • 最常见治疗相关不良事件为疲乏(75.0%)、恶心(69.4%)和腹泻(61.1%)

核心结论

  • 莫西司他在R/R DLBCL和FL中单药活性有限,但获得临床获益的患者实现了长期疾病控制,安全性可接受。
  • 作者认为该类药物值得进一步研究,包括识别更可能对莫西司他应答的患者,或与其他药物联合使用。

研究设计与样本

  • 这是一项2期研究,评估莫西司他治疗复发或难治性DLBCL和FL患者。
  • 共72例患者接受莫西司他治疗,起始剂量为70-110 mg,每周三次(TIW),4周为一周期。

主要发现

  • DLBCL队列(n=41)最佳总缓解率为18.9%(95%CI 7.2, 32.2)。
  • FL队列(n=31)最佳总缓解率为11.5%(95%CI 1.7, 20.7)。
  • 10例缓解者中7例缓解持续时间≥90天。
  • DLBCL队列54.1%、FL队列73.1%的患者获得临床获益(缓解或疾病稳定)。
  • 缓解者无进展生存期在DLBCL队列为1.8至22.8个月,在FL队列为11.8至26.3个月。

关键数值与推荐

  • DLBCL队列最佳总缓解率18.9%(95%CI 7.2, 32.2),FL队列11.5%(95%CI 1.7, 20.7)。
  • DLBCL队列临床获益率54.1%,FL队列73.1%。
  • 最常见治疗相关不良事件为疲乏(75.0%)、恶心(69.4%)和腹泻(61.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出莫西司他在R/R DLBCL和FL中单药活性有限。
  • 作者指出该类药物值得进一步研究,包括识别更可能对该药应答的患者,或与其他药物联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deregulation of histone deacetylase (HDAC) is important in the pathogenesis of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Mocetinostat, an isotype-selective HDAC inhibitor, induces accumulation of acetylated histones, cell cycle arrest and apoptosis in several cancers. This phase 2 study evaluated mocetinostat in patients with relapsed/refractory (R/R) DLBCL and FL. Seventy-two patients received mocetinostat (starting doses: 70-110 mg TIW, 4-week cycles). The best overall response rate (95% CI) was 18·9% (7·2, 32·2) for the DLBCL cohort (n = 41), and 11·5% (1·7, 20·7) for the FL cohort (n = 31). Responses were durable (≥90 days in 7 of 10 responses). Overall, 54·1% and 73·1% of patients derived clinical benefit (response or stable disease) from mocetinostat in the DLBCL and FL cohorts, respectively. Progression-free survival ranged from 1·8 to 22·8 months and 11·8 to 26·3 months in responders with DLBCL and FL, respectively. The most frequent treatment-related adverse events were fatigue (75·0%), nausea (69·4%) and diarrhoea (61·1%). Although mocetinostat had limited single-agent activity in R/R DLBCL and FL, patients with clinical benefit had long-term disease control. The safety profile was acceptable. This drug class warrants further investigation, including identifying patients more likely to respond to this agent, or in combination with other agents.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Batlevi CL, Crump M, Andreadis C, et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol. 2017. PMID: 28440559. doi:10.1111/bjh.14698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。